Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To report safety and efficacy of intravitreal injection of bevacizumab in patients with cystoid macular edema secondary to cataract surgery.

• Phase: Phase 3

Details

• Lead Sponsor: Asociación para Evitar la Ceguera en México
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Pseudophakic eyes with macular edema

Exclusion Criteria:

• Other retinopathies